EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Validation of new ACR/EULAR 2022 classification criteria for anti-neutrophil cytoplasmic antibody–associated vasculitis

Ken-Ei Sada iD, Shinya Kaname, Tomoaki Higuchi, Shunsuke Furuta, Kenji Nagasaka, Toshihiro Nanki, Naotake Tsuboi, Koichi Amano, Hiroaki Dobashi, Keiju Hiromura, Masashi Bando, Takashi Wada und 3 weitere

Modern Rheumatology · 2023

DOI: 10.1093/mr/road017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Ken-Ei Sada und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology, Kochi Medical School, Nankoku, Japan. Hauptthemen laut MEDLINE: Granulomatosis with Polyangiitis, Churg-Strauss Syndrome, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective of this study was to compare the American College of Rheumatology/European Alliance of Associations for Rheumatology 2022 criteria with the previous classification algorithm for anti-neutrophil cytoplasmic antibody–associated vasculitis.

Methods

We used data from two nationwide, prospective, inception cohort studies. The enrolled patients were classified as having eosinophilic granulomatosis with polyangiitis (EGPA), granulomatosis with polyangiitis (GPA), or microscopic polyangiitis (MPA) according to the new criteria; these criteria were compared with Watts’ algorithm.

Results

Among 477 patients, 10.7%, 9.9%, and 75.6% were classified as having EGPA, GPA, and MPA, respectively; 6.1% were unclassifiable. Three patients met both the EGPA and MPA criteria, and eight patients met both the GPA and MPA criteria. Of 78 patients with GPA classified using Watts’ algorithm, 27 (34.6%) patients were reclassified as having MPA. Ear, nose, and throat involvement was significantly less frequent in patients reclassified as having MPA than in those reclassified as having GPA. Of 73 patients unclassifiable using Watts’ algorithm, 62 were reclassified as having MPA. All patients reclassified as having MPA were myeloperoxidase-anti-neutrophil cytoplasmic antibody positive, and 46 had interstitial lung disease.

Conclusion

Although the American College of Rheumatology/European Alliance of Associations for Rheumatology 2022 criteria cause overlapping multiple criteria fulfilments in some patients, those items contribute to classifying unclassifiable patients using Watts’ algorithm into MPA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Granulomatosis with PolyangiitisChurg-Strauss SyndromeAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisMicroscopic PolyangiitisHumansUnited StatesProspective StudiesAntibodies, Antineutrophil Cytoplasmic

Stichwörter der Autor:innen

Anti-neutrophil cytoplasmic antibodyclassification criteriaeosinophilic granulomatosis with polyangiitisgranulomatosis with polyangiitismicroscopic polyangiitis

Substanzen

Antibodies, Antineutrophil Cytoplasmic

Autor:innen und Institutionen

  • Department of Clinical Epidemiology, Kochi Medical School, Nankoku, Japan.
  • Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan.
  • Division of Multidisciplinary Management of Rheumatic Diseases, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
  • Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
  • Department of Allergy and Clinical Immunology, Chiba University, Chiba, Japan.

ORCID-Profile: Ken-Ei Sada

Zitieren

APA

Sada, K. E., Kaname, S., Higuchi, T., Furuta, S., Nagasaka, K., Nanki, T., Tsuboi, N., Amano, K., Dobashi, H., Hiromura, K., Bando, M., Wada, T., Arimura, Y., Makino, H., & Harigai, M. (2023). Validation of new ACR/EULAR 2022 classification criteria for anti-neutrophil cytoplasmic antibody–associated vasculitis. Modern Rheumatology. https://doi.org/10.1093/mr/road017

Vancouver

Sada KE, Kaname S, Higuchi T, Furuta S, Nagasaka K, Nanki T, et al. Validation of new ACR/EULAR 2022 classification criteria for anti-neutrophil cytoplasmic antibody–associated vasculitis. Modern Rheumatology. 2023. doi:10.1093/mr/road017

BibTeX
@article{Sada2023,
  author = {Sada, Ken-Ei and Kaname, Shinya and Higuchi, Tomoaki and Furuta, Shunsuke and Nagasaka, Kenji and Nanki, Toshihiro and Tsuboi, Naotake and Amano, Koichi and Dobashi, Hiroaki and Hiromura, Keiju and Bando, Masashi and Wada, Takashi and Arimura, Yoshihiro and Makino, Hirofumi and Harigai, Masayoshi},
  title = {Validation of new ACR/EULAR 2022 classification criteria for anti-neutrophil cytoplasmic antibody–associated vasculitis},
  journal = {Modern Rheumatology},
  year = {2023},
  doi = {10.1093/mr/road017}
}
Kostenlos starten →